|
|
Big Pharma manages symptoms. This startup resolves the root cause. |
For over 125 years, inflammation care has relied on symptom suppression. |
Aspirin was groundbreaking in its time — but in a world plagued by chronic inflammation — we all need something better. |
Sen-Jam is pioneering the first true leapfrog advance in inflammatory care. |
Q: What do cancer, heart disease, and rheumatoid arthritis have in common? A: Inflammation drives them all. |
Inflammation is a silent epidemic, at the core of countless chronic diseases. Yet today’s treatments only mask symptoms or worse suppress the body’s immune system, leaving the root cause untouched. |
Sen-Jam changes that. |
With its revolutionary PAIR (Pleiotropic Anti-Inflammatory Remedies) technology, Sen-Jam comprehensively targets inflammation at its source, delivering the most transformative advance since aspirin was invented. |
This isn’t just an improvement—it’s a paradigm shift. |
|
How does Sen-Jam work? |
Most therapies target single inflammatory pathways — like fighting a wildfire with a squirt gun 🔥🔫 |
PAIR acts like a maestro, coordinating multiple inflammatory pathways for additive, powerful results. |
In a Phase 2 clinical trial for SJP-002C, PAIR demonstrated: |
Strong efficacy in treating respiratory inflammation An exceptional safety profile, addressing both symptoms and roo causes. |
“Our approach is so simple and powerful, it’s like discovering the next aspirin — an essential solution that changes everything. |
Why invest in Sen-Jam? |
Massive TAM: Inflammation underlies a wide range of diseases, driving a $125 billion market projected by 2030. Unprecedented Innovation: 60 patents strong, Sen-Jam’s groundbreaking platform is positioned to disrupt the $1.48T pharma industry. Past successful exits: Backed by a team of scientific experts and entrepreneurial veterans with a proven track record. |
“This is the inflection point. Science, timing, and market demand have aligned for the biggest advance in 125 years. |
Perks of investing |
Invest any amount and get Fractional Royalty Rights as annual dividends Bonus Incentives for Larger Investments: $25k+: 10% bonus in stock $50k+: 12% bonus in stock $100k+: 14% bonus in stock |
Note: these favorable terms sunset February 15th |
Be part of the next breakthrough in healthcare. |
Express interest |
Click the button below to: |
Gain access to exclusive updates Take your place in shaping the future of healthcare Invest in the most transformative advance in over a century |
The future of inflammation care starts now. |
Transform health. Transform lives. Transform your portfolio. |
|
To learn more about Sen-Jam without giving permission to email, click here. |
|
📰 Market Headlines |
|
Tech stocks crashed yesterday as Chinese AI startup DeepSeek rattled faith in US artificial intelligence dominance. |
The Nasdaq dropped 3%, the S&P 500 fell 1.5%, and the Dow gained 0.6%. |
Nvidia fell 17%, losing $589 billion in market value. |
President Trump announced plans to eliminate DEI programs from the military via executive order today. |
New Zealand eased digital nomad visas, allowing 90-day stays to boost tourism. |
Israel confirmed eight Gaza hostages set for release were killed in captivity. |
|
🎰 Alts this week |
🚪 TrueCrowd shuts down |
🎨 Sotheby’s art sales down 28%, new focus on Saudi Arabia |
🍗 Popeyes announces collab with Don Julio tequila |
💵 Rare bicentennial quarter hits $15 million valuation |
⚾️ Ultimate Jewish baseball card collection up for auction |
🧠 Make yourself heard |
GDP comes out Thursday with a consensus of around 2.9% YoY on Kalshi. This represents a decline from 3.1% in Q3 to 3.2% a year ago. |
GDP will come in |
|
PS, if you’re not trading on Kalshi, you’re missing out on free money. |
|
📊 Ideas, trends, and analysis |
| Despite regional conflict, oil has traded in a tight band in the last 30 months. |
|
New home sales rose 3.6% in December, with the median price up 2.1% to $427,000. Oil fell as President Trump demanded OPEC cut prices and roll back environmental restrictions. |
😱 Fear and Greed Index |
|
|
📊 Winners and losers |
|
|
Earnings, upgrades, and acquisitions |
SoFi dropped 12.1% on weak 2025 guidance. AT&T climbed 6.4% despite cash flow falling 25%. Western Alliance beat Q4 expectations; shares rose 3%. Nucor posted $1.22 EPS on $7.08 billion revenue; shares dipped 2%. |
Market movers |
DeepSeek's R1 model disrupted AI by matching top chatbots' performance while slashing development costs and energy use. The FTC sued John Deere over alleged repair monopolies raising farmer costs. Blackstone forecasted $210 billion in CLO sales in 2025 from increased M&A activity. Bridgestone announced plans to cut 1,760 jobs across the Americas and close a Tennessee plant. |
|
|
🌍 Global Perspectives | | 🇨🇩 🇷🇼 M23 rebels seized Congo’s Goma, displacing tens of thousands due to heavy fighting. 🇰🇷 South Korea indicted impeached President Yoon for rebellion over December’s martial law. 🇵🇸 Gaza faces a health crisis, with 75% of hospitals destroyed and 30,000 needing lifelong care. 🇨🇴 🇺🇸 Colombia avoided a US trade war after calls for diplomacy from business leaders. 🇧🇾 Belarus’s Lukashenko won 86.8% of votes in a widely disputed election. |
|
|
|
📊 Crypto | | Nasdaq proposed in-kind redemptions for BlackRock’s Bitcoin ETF to streamline costs. Bitcoin fell below $100,000, triggering $855 billion in liquidations. The SEC eliminated SAB 121, letting banks treat Bitcoin as an asset, not a liability. MicroStrategy announced plans to sell 2.5 million shares for Bitcoin buys after purchasing $1.1B BTC. | |
|
|
🎤 What you said last time |
|
What You Had to Say:
“You can’t trust China, this is just a fact - no one in China trusts China” |
|
📺 What to Watch Today |
| Googly eyes cost Bend $1,500 in roundabout art repairs |
|
|
That’s all for today. Did I miss anything? Smash the reply button to let me know. | Cheers, | Wyatt |
|
|
|
|
|
